Comorbidities in Black Patients with HIV/AIDS

  • M. Keith Rawlings
  • Oluwatoyin Adeyemi


Chronic diseases account for three-quarters of the U.S. health care expenditures and a majority of early deaths and loss of productive years of life. Health disparities exist among the common chronic diseases, such as hypertension, diabetes mellitus, HIV/AIDS, cardiovascular disease, renal disease, and obesity, with ethnic minorities and the poor having higher incidence or worse outcomes.1


Sustained Virologic Response Sustained Virologic Response Rate African American Patient Early Virologic Response African American Subject 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Crook ED, Peters M. Health disparities in chronic diseases: where the money is. Am J Med Sci. 2008 Apr;335(4):266–70PubMedCrossRefGoogle Scholar
  2. 2.
    Alter MJ, Kruszon-Moran D, Nainan OV,. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New Engl J Med 1999;341:556–62PubMedCrossRefGoogle Scholar
  3. 3.
    National Institutes of Health Consensus Development Conference Statement Management of Hepatitis C: Hepatology 2002;36:5 suppl 1:S3–20Google Scholar
  4. 4.
    Sulkowski MS, et al. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 2000;suppl 1:s77–84Google Scholar
  5. 5.
    Broers B,. Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS 1998;12:2059–66PubMedCrossRefGoogle Scholar
  6. 6.
    Sherman KE,. Comparison of methodologies for quantification of hepatitis C virus (HCV) RNA in patients coinfected with HCV and human immunodeficiency virus. Clin Infect Dis. 2002 Aug 15;35(4):482–7. Epub 2002 Jul 22PubMedCrossRefGoogle Scholar
  7. 7.
    Bica I, McGovern B, Dhar R,. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001 Feb 1;32(3):492–7. Epub 2001 Jan 23PubMedCrossRefGoogle Scholar
  8. 8.
    Monga HK, Rodriguez-Barradas MC, Breaux K,. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. 2001 Jul 15;33(2):240–7. Epub 2001 Jun 15Google Scholar
  9. 9.
    Rosenthal E, Pialoux G, Bernard N,. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 2007 Mar;14(3):183–8PubMedCrossRefGoogle Scholar
  10. 10.
    Hobbs F, Stoops N; 2002. Available at
  11. 11.
    Pearlman BL. Hepatitis C virus infection in African Americans. Clin Infect Dis. 2006 Jan 1;42(1):82–91. Epub 2005 Nov 29. ReviewPubMedCrossRefGoogle Scholar
  12. 12.
    Lau JY, Davis GL, Prescott LE,. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Ann Intern Med. 1996 May 15;124(10):868–76PubMedCrossRefGoogle Scholar
  13. 13.
    Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African Americans: summary of a workshop. Gastroenterology. 2000 Nov;119(5):1385–96PubMedCrossRefGoogle Scholar
  14. 14.
    Bonacini M, Groshen MD, Yu MC, Govindarajan S, Lindsay KL. Chronic hepatitis C in ethnic minority patients evaluated in Los Angeles County. Am J Gastroenterol. 2001 Aug;96(8):2438–41PubMedCrossRefGoogle Scholar
  15. 15.
    Sterling RK, Stravitz RT, Luketic VA,. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol. 2004 Jun;2(6):469–73PubMedCrossRefGoogle Scholar
  16. 16.
    El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004 Nov;127(5 Suppl 1):S27–34PubMedCrossRefGoogle Scholar
  17. 17.
    Nguyen MH, Whittemore AS, Garcia RT,. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol. 2004 Sep;2(9):820–4PubMedCrossRefGoogle Scholar
  18. 18.
    Sulkowski MS, Mehta SH, Torbenson MS,. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007 Oct 18;21(16):2209–16PubMedCrossRefGoogle Scholar
  19. 19.
    Maida I, Nunez M, Gonzalez-lahoz J. Liver transplantation in HIV–HCV coinfected candidates: what is the most appropriate time for evaluation? AIDS Res Hum Retroviruses. 2005 Jul;21(7):599–601PubMedCrossRefGoogle Scholar
  20. 20.
    Brau N, Fox RK, Xiao P,. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol. 2007 Oct;47(4):527–37. Epub 2007 Jul 19PubMedCrossRefGoogle Scholar
  21. 21.
    Lechner F, Wong DK, Dunbar PR,. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med. 2000 May 1;191(9):1499–512PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Sugimoto K, Stadanlick J, Ikeda F,. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology. 2003 Mar;37(3):590–9PubMedCrossRefGoogle Scholar
  23. 23.
    Thio CL, Thomas DL, Goedert JJ,. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 2001 Jul 1;184(1):16–21. Epub 2001 May 30PubMedCrossRefGoogle Scholar
  24. 24.
    Oleksyk TK, Thio CL, Truelove AL,. Single nucleotide polymorphisms and haplotypes in the IL10 region associated with HCV clearance. Genes Immun. 2005 Jun;6(4):347–57PubMedCrossRefGoogle Scholar
  25. 25.
    Falck-Ytter Y, Kale H, Mullen KD,. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002 Feb 19;136(4):288–92PubMedCrossRefGoogle Scholar
  26. 26.
    Fleming CA, Craven DE, Thorton D,. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis. 2003 Jan 1;36(1):97–100. Epub 2002 Dec 11PubMedCrossRefGoogle Scholar
  27. 27.
    Adeyemi OM, Jensen D, Attar B,. Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. AIDS Patient Care STDS. 2004 Apr;18(4):239–45PubMedCrossRefGoogle Scholar
  28. 28.
    Butt AA, Justice AC, Skanderson M,. Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects. Aliment Pharmacol Ther. 2006 Aug 15;24(4):585–91PubMedCrossRefGoogle Scholar
  29. 29.
    Backus LI, Boothroyd DB, Phillips BR,. Pretreatment assessment and predictors of hepatitis C virus treatment in US veterans coinfected with HIV and hepatitis C virus. J Viral Hepat. 2006 Dec;13(12):799–810PubMedCrossRefGoogle Scholar
  30. 30.
    Bräu N, Salvatore M, Ríos-Bedoya CF,. J Hepatol. 2006 Jan;44(1):47–55. Epub 2005 Jul 27PubMedCrossRefGoogle Scholar
  31. 31.
    Reddy KR, Hoofnagle JH, Tong MJ,. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999 Sep;30(3):787–93PubMedCrossRefGoogle Scholar
  32. 32.
    McHutchison JG, Poynard T, Pianko S,. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology. 2000 Nov;119(5):1317–23PubMedCrossRefGoogle Scholar
  33. 33.
    De Maria N, Colantoni A, Idilman R,. Impaired response to high-dose interferon treatment in African Americans with chronic hepatitis C. Hepatogastroenterology. 2002 May–Jun;49(45):788–92PubMedGoogle Scholar
  34. 34.
    Kinzie JL, Naylor PH, Nathani MG,. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat. 2001 Jul;8(4):264–9PubMedCrossRefGoogle Scholar
  35. 35.
    Theodore D, Shiffman ML, Sterling RK,. Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C. Dig Dis Sci. 2003 Jan;48(1):140–5PubMedCrossRefGoogle Scholar
  36. 36.
    Zeuzem S, Feinman SV, Rasenack J,. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000 Dec 7;343(23):1666–72PubMedCrossRefGoogle Scholar
  37. 37.
    Linday KL, Trepo C, Heintges T,. Hepatology. 2001 Aug;34(2):395–403CrossRefGoogle Scholar
  38. 38.
    Manns MP, McHutchison JG, Gordon SC,. Lancet. 2001 Sep 22;358(9286):958–65PubMedCrossRefGoogle Scholar
  39. 39.
    Fried MW, Shifmman ML, Reddy KR,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. N Engl J Med. 2002;347:975–82PubMedCrossRefGoogle Scholar
  40. 40.
    Jeffers L, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 2004 Jun;39(6):1702–8PubMedCrossRefGoogle Scholar
  41. 41.
    Muir AJ, Bornstein JD, Killenberg PG,. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004 May 27;350(22):2265–71PubMedCrossRefGoogle Scholar
  42. 42.
    Conjeevaram HS, Fried MW, Jeffers LJ,. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006 Aug;131(2):470–7PubMedCrossRefGoogle Scholar
  43. 43.
    Jacobson IM, Brown RS,. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology. 2007 Oct;46(4):982–90PubMedCrossRefGoogle Scholar
  44. 44.
    Carrat F, Bani-Sadr F, Pol S,. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004 Dec 15;292(23):2839–48PubMedCrossRefGoogle Scholar
  45. 45.
    Toriani FJ, Rodriguez-Torres M, Rockstroh JK,. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004 Jul 29;351(5):438–50CrossRefGoogle Scholar
  46. 46.
    Chung RY, Andersen J, Volberding P, Robbins GK,. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004 Jul 29;351(5):451–9PubMedCrossRefGoogle Scholar
  47. 47.
    Layden-Almer JE, Ribeiro RM, Wiley T,. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology. 2003 Jun;37(6):1343–50PubMedCrossRefGoogle Scholar
  48. 48.
    Jain M, Shelton J, Liston N, et al. 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008). Boston, MA. February 3–6, 2008. Abstract 1077Google Scholar
  49. 49.
    Kimball P, Elswick RK, Shiffman M. Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy. J Med Virol. 2001 Nov;65(3):510–6PubMedCrossRefGoogle Scholar
  50. 50.
    Ikura Y, Morimoto H, Hohmura H,. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. Am J Gastroenterol. 1996;91:1367–73PubMedGoogle Scholar
  51. 51.
    Barton Al, Banner BF, Cable EE,. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am J Clin Pathol. 1995 Apr;103(4):419–24PubMedGoogle Scholar
  52. 52.
    Van Thiel DH, Friedlander L, Fagiuoli S,. Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol. 1994 Mar;20(3):410–5PubMedCrossRefGoogle Scholar
  53. 53.
    Ioannou GN, Dominitz JA, Weiss NS,. Racial differences in the relationship between hepatitis C infection and iron stores. Hepatology. 2003 Apr;37(4):795–801PubMedCrossRefGoogle Scholar
  54. 54.
    CDC 2007. Summary Heath Statistic for US Adults: 2006. Table 2.
  55. 55.
    CDC 2007. Heath United States, 2007. Table 35.
  56. 56.
    Phillips et al. 14th CROI, 2007Google Scholar
  57. 57.
    Mondy KE, de las Fuentes L, Waggoner A,. Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy. AIDS. 2008 Apr 23;22(7):849–56PubMedCentralPubMedCrossRefGoogle Scholar
  58. 58.
    D:A:D Study Group. Use of nucleoside transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; Published Online April 2, 2008Google Scholar
  59. 59.
    Sabin CA, d’Arminio Monforte A, Friis-Moller N,. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin Infect Dis. 2008 Apr 1;46(7):1101–10PubMedCrossRefGoogle Scholar
  60. 60.
    Choudhary SA, et al. 43rd ICAAC. Chicago, 2003. H-1937Google Scholar
  61. 61.
    Law MG, Friis-Møller N, El-Sadr WM,. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med. 2006 May;7(4):218–30PubMedCrossRefGoogle Scholar
  62. 62.
    Garcia-Lazaro M,. Variability in coronary risk assessment in HIV-infected patients. Med Clin (Barc). 2007 Oct 20;129(14):521–4CrossRefGoogle Scholar
  63. 63.
    Kaplan RC,. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis. 2007 Oct 15;45(8):1074–81. Epub 2007 Sep 12PubMedCrossRefGoogle Scholar
  64. 64.
    May M,. A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. Int J Epidemiol. 2007 Dec;36(6):1309–18. Epub 2007 Jul 25PubMedCrossRefGoogle Scholar
  65. 65.
    Huang SS,. Reversal of human immunodeficiency virus type 1-associated hematosuppression by effective antiretroviral therapy. Clin Infect Dis. 2000 Mar;30(3):504–10PubMedCrossRefGoogle Scholar
  66. 66.
    Sullivan PS,. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood. 1998 Jan 1;91(1):301–8PubMedGoogle Scholar
  67. 67.
    Aalto-Setälä K,. Folic acid absorption in patients infected with the human immunodeficiency virus. J Intern Med. 1991 Sep;230(3):227–31CrossRefGoogle Scholar
  68. 68.
    Guyatt GH,. Laboratory diagnosis of iron-deficiency anemia: an overview. J Gen Intern Med. 1992 Mar–Apr;7(2):145–53PubMedCrossRefGoogle Scholar
  69. 69.
    Mildvan D. Implications of anemia in human immunodeficiency virus, cancer, and hepatitis C virus. Clin Infect Dis. 2003;37 Suppl 4:S293–6PubMedCrossRefGoogle Scholar
  70. 70.
    Mildvan D,. Prevalence of anemia and correlation with biomarkers and specific antiretroviral regimens in 9690 human-immunodeficiency-virus-infected patients: findings of the Anemia Prevalence Study. Curr Med Res Opin. 2007 Feb;23(2):343–55PubMedCrossRefGoogle Scholar
  71. 71.
    Volberding P, Levine AM, Dieterich D,. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis. 2004 May 15;38(10):1454–63. Epub 2004 Apr 27PubMedCrossRefGoogle Scholar
  72. 72.
    Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005 Jan 6;352(1):48–62PubMedCrossRefGoogle Scholar
  73. 73.
    Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):395–400PubMedCrossRefGoogle Scholar
  74. 74.
    Saint-Marc T, Partisani M, Poizot-Martin I,. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS. 2000 Jan 7;14(1):37–49PubMedCrossRefGoogle Scholar
  75. 75.
    Saves M, Raffi F, Capeau J,. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2002 May 15;34(10):1396–405. Epub 2002 Apr 22PubMedCrossRefGoogle Scholar
  76. 76.
    Bacchetti P, Gripshover B, Grunfeld C,. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr. 2005;40:121–131PubMedCrossRefGoogle Scholar
  77. 77.
    Fat Redistribution and Metabolic Change in HIV Infection (FRAM) Writing Team. Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr. 2006 Aug 15;42(5):562–71Google Scholar
  78. 78.
    Hadigan C, Meigs JB, Wilson PW,. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis. 2003 Apr 1;36(7):909–16. Epub 2003 Mar 20PubMedCrossRefGoogle Scholar
  79. 79.
    Miller J, Carr A, Emery S,. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med. 2003 Jul;4(3):293–301PubMedCrossRefGoogle Scholar
  80. 80.
    Lichtenstein KA, Ward DJ, Moorman AC,. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001 Jul 27;15(11):1389–98PubMedCrossRefGoogle Scholar
  81. 81.
    Bogner JR, Vielhauer V, Beckmann RA,. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):237–44PubMedGoogle Scholar
  82. 82.
    van Vonderen MG, et al. 4th IAS Conference. Sydney, 2007. Abstract TuPeB077Google Scholar
  83. 83.
    Lazzaretti R, et al. 4th IAS Conference. Sydney, 2007. Abstract WeAB303Google Scholar
  84. 84.
    Carr A, Ory D. Does HIV cause cardiovascular disease? PLoS Med. 2006 Nov;3(11):e496PubMedCentralPubMedCrossRefGoogle Scholar
  85. 85.
    Mallon PW, Miller J, Kovacic JC,. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men–a randomized, placebo-controlled study. AIDS. 2006 Apr 24;20(7):1003–10PubMedCrossRefGoogle Scholar
  86. 86.
    Carr A, Workman C, Carey D, et al. Lancet. 2004 Feb 7;363(9407):429–38PubMedCrossRefGoogle Scholar
  87. 87.
    Valantin MA, Aubron-Olivier C, Ghosn J,. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS. 2003 Nov 21;17(17):2471–7PubMedCrossRefGoogle Scholar
  88. 88.
    Levan P, Nguyen TH, Lallemand F,. Correction of facial lipoatrophy in HIV-infected patients on highly active antiretroviral therapy by injection of autologous fatty tissue. AIDS. 2002;16:1985–1987PubMedCrossRefGoogle Scholar
  89. 89.
    Guaraldi G, De Fazio D, Orlando G,. Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat tissue transplantation. Clin Infect Dis. 2005 Jan 15;40(2):e13–5. Epub 2004 Dec 21PubMedCrossRefGoogle Scholar
  90. 90.
    CDC. Prevalence of overweight and obesity among adults with diagnosed diabetes–United States, 1988–1994 and 1999–2002. MMWR Morb Mortal Wkly Rep. 2004 Nov 19;53(45):1066–8Google Scholar
  91. 91.
    Amorosa, et al. A Tale of 2 Epidemics: The Intersection between Obesity and HIV Infection in the Urban United States (CROI 2004). San Francisco, CA. Abstract 879Google Scholar
  92. 92.
    C Hadigan, Yawetz S, Thomas A,. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med. 2004 May 18;140(10):786–94PubMedCrossRefGoogle Scholar
  93. 93.
    Gavrila A, Hsu W, Tsiodras S,. Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 × 2 factorial, randomized, double-blinded, placebo-controlled trial. Clin Infect Dis. 2005 Mar 1;40(5):745–9. Epub 2005 Feb 7PubMedCrossRefGoogle Scholar
  94. 94.
    Schutt M, Meier M, Meyer M,. The HIV-1 protease inhibitor indinavir impairs insulin signalling in HepG2 hepatoma cells. Diabetologia. 2000 Sep;43(9):1145–8PubMedCrossRefGoogle Scholar
  95. 95.
    Noor MA, Seneviratne T, Aweeka FT,. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS. 2002 Mar 29;16(5):F1–8PubMedCentralPubMedCrossRefGoogle Scholar
  96. 96.
    Blass SC, Ellinger S, Vogel M,. Overweight HIV Patients with Abdominal Fat Distribution Treated with Protease Inhibitors are at High Risk for Abnormalities in Glucose Metabolism – A Reason for Glycemic Control. Eur J Med Res. 2008 May 26;13(5):209–14PubMedGoogle Scholar
  97. 97.
    Manuthu EM, Joshi MD, Lule GN, Karari E. Prevalence of dyslipidemia and dysglycaemia in HIV infected patients. East Afr Med J. 2008 Jan;85(1):10–7PubMedCrossRefGoogle Scholar
  98. 98.
    Schambelan M, Benson CA, Carr A,. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr. 2002 Nov 1;31(3):257–75PubMedCrossRefGoogle Scholar
  99. 99.
    Schwartz EJ,. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol. 2005 Aug;16(8):2412–20. Epub 2005 Jun 29PubMedCrossRefGoogle Scholar
  100. 100.
    Lucas GM, Mehta SH, Atta MG,. End-stage renal disease and chronic kidney disease in a cohort of African American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004. AIDS. 2007 Nov 30;21(18):2435–43PubMedCrossRefGoogle Scholar
  101. 101.
    Szczech L, Hoover DR, Feldman JG,. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis. 2004 Oct 15;39(8):1199–206. Epub 2004 Sep 27PubMedCrossRefGoogle Scholar
  102. 102.
    Herman ES, Klotman PE. HIV-associated nephropathy: Epidemiology, pathogenesis, and treatment. Semin Nephrol. 2003 Mar;23(2):200–8PubMedCrossRefGoogle Scholar
  103. 103.
    Martins D, Tareen N, Norris KC. The epidemiology of end-stage renal disease among African Americans. Am J Med Sci. 2002 Feb;323(2):65–71PubMedCrossRefGoogle Scholar
  104. 104.
    Freedman, Soucie JM, Stone SM, Pegram S. Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis. 1999 Aug;34(2):254–8PubMedCrossRefGoogle Scholar
  105. 105.
    Abbott KC, Hypolite I, Welch PG, Agodoa LY. Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretroviral therapy era. J Nephrol. 2001 Sep–Oct;14(5):377–83PubMedGoogle Scholar
  106. 106.
    Hailemariam S, Walder M, Burger HR, et al. Renal pathology and premortem clinical presentation of Caucasian patients with AIDS: an autopsy study from the era prior to antiretroviral therapy. Swiss Med Wkly. 2001 Jul 14;131(27–28):412–7PubMedGoogle Scholar
  107. 107.
    Monahan M, Tanji N, Klotman PE,. HIV-associated nephropathy: an urban epidemic. Semin Nephrol. 2001 Jul;21(4):394–402PubMedCrossRefGoogle Scholar
  108. 108.
    Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006 Jan 19;354(3):251–60PubMedCrossRefGoogle Scholar
  109. 109.
    Rawlings MK, et al. IAC 2008. Abstract 9572Google Scholar
  110. 110.
    Marconi P, Lorenzini P, Corpolongo A, et al. Black race and degree of immunisuppression predict rate of proteinuria before and after combination antiretroviral treatment (cART) in Italian HIVinfected population. XVII International AIDS Conference. Mexico City; 2008 Poster THEP0197Google Scholar
  111. 111.
    Palella F, Li X, Kingsley L, et al. Proteinuria, glomerular filtration rate reductions, and associated factors among HIV-infected and -uninfected men in the Multicenter AIDS Cohort Study. 15th CROI; 2008; Boston. Abstract 973Google Scholar
  112. 112.
    Fine DM, Perazella MA, Lucas GM, Atta MG. Kidney biopsy in HIV: beyond HIV-associated nephropathy. Am J Kidney Dis. 2008 Mar;51(3):504–14. Epub 2008 Feb 7PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Cook County Hospital and Rush University medical CollegeILUSA

Personalised recommendations